JPMorgan raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $55 from $50 and keeps a Neutral rating on the shares. Heading into the European Society of Cardiology meeting this Friday, the firm updated the company’s model to reflect higher projections for TTR silencers on the back of recent key opinion leader feedback. Now that HELIOS-B has succeeded, what is good for Amvuttra is good for the silencer class, the analyst tells investors in a research note. JPMorgan generally expects Ionis to trade in the same direction as Alnylam (ALNY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Canaccord reiterates Buy rating on Clene following ‘intriguing’ new data
- Ionis Pharmaceuticals treatment of polycythemia vera granted orphan status
- Ionis Pharmaceuticals price target raised to $51 from $45 at Barclays
- Ionis downgraded to Market Perform from Outperform at BMO Capital
- Ionis Pharmaceuticals says ‘on track to achieve 2024 financial guidance’